14 kinds of health insurance catalog of cancer drug prices cut again, there is limited room for decline

in order to further reduce the economic burden of cancer patients, the State Medical Security Administration issued on August 11 "on the pre-negotiation of anti-cancer drug medical insurance payment standards and procurement price adjustment notice", lowered 14 kinds of early national negotiations anti-cancer drugs payment standards and procurement prices, and required that by the end of September all provincial drug centralized procurement platforms in accordance with the adjusted new prices of open online procurement. On September 1, interface reporters learned from Beijing Cancer Hospital, Peking University Third Hospital and other hospitals that the hospital has received a price reduction notice, the pharmacy system on August 31 has been on the medical insurance catalog of 14 kinds of anti-cancer drugs 9 drugs have been adjusted accordinglyThe adjusted payment standard for cancer drugs priced by tablet or bottle is reduced by a few yuan, tens of dollars and hundreds of dollars (see table below).Compared to the average price reduction of 36 high-priced drugs in 2017, the price of the 14 cancer drugs fell slightly, by an average of 4.86 percent between 3% and 7.8%. In 2017, when the national medical insurance drug catalogue was adjusted, in view of the fact that some patents and exclusive drugs have high clinical value and relatively expensive prices at the same time, a negotiating and negotiating mechanism between medical insurance operators and pharmaceutical companies was established, and 36 high-priced drugs were included in the scope of the catalogue after negotiating price reductions and determining the national uniform standard of payment for medical insurance. "This 14 anti-cancer drugs price reduction, is in 2017 after the anti-cancer drug negotiations to reduce the price of the price of another price reduction, is the state after the benefit of the hope of the people, the price again fell in the space is limited." Industry sources with many years of experience in medical insurance research said, "Drug prices are difficult to significantly reduce prices, first, although the state finance sector in health insurance investment growth rate has exceeded many countries, but the provinces of the solvency of health insurance is very different; The person said that the medical surface is medicine, in fact, lies in the medical, public hospitals to implement drug proportion assessment, structural mismatch, "the value of doctors in public hospitals is underestimated, the abolition of drug add-on, drug ratio reduced to 40%, although the state set up medical service fees for doctors to compensate for technical labor, but this incentive system is limited, doctors' income is still very low, in this case, the number of patients will not increase is also a problem, or the need for the state to introduce more incentives for doctors, compensation mechanismAt the same time, medical insurance, medicine, medical care, the three doctors linked together, there must be a multi-level medical assurance mechanismXu Weicai, deputy director of the health bureau of Shanyang County, Shaanxi Province, told the interface reporter, "India's generic incentive mechanism has greatly reduced drug prices, but our country's laws are different from India's." Based on our system, in order to solve the problem of ordinary people, especially anti-cancer medicine can not afford, one should be due to the policy caused by the price of drugs water squeeze clean, the way is to modify the policySecond, the establishment of the market to determine the price mechanism, so that drug prices less power interference, this is too difficult and far awayAt present, the national reunification negotiations are estimated to be only temporary measuresThird, increase the intensity of health insurance coverage, especially cancer and other rare diseases of rare diseases of the protection of drugsInterface journalists from the public information query, the State Medical Security Administration issued on August 11 th issued a price adjustment notice for the payment of anti-cancer drugs, the country has 15 provinces in the medical insurance catalog of anti-cancer drug prices have been revised down again, respectively, Hubei, Gansu, Guangdong, Hunan, Hainan, Jiangxi, Henan, Shaanxi, Liaoning, Beijing, Sichuan, Shandong, Shanghai, Jilin, Zhejiang and other provinces and cities. On the other hand, recently, the relevant departments of the state for anti-cancer drugs to reduce prices, to ensure that the masses of basic drug demand frequently introduced measures. On August 17, the State Health Insurance Administration (NSC) posted on the Chinese government's website "Notice on the Release of the Scope of Special Negotiations on The Admission of Cancer Drugs to 2018", which stated that, in accordance with the requirements of the State Council, the State Insurance Administration had accelerated the special negotiations on access to cancer drugs, organized more than 70 experts from 20 provinces across the country to review, select and vote, and confirmed in writing that 18 varieties of 12 enterprises were included in the special drug negotiationsA new round of negotiations on access to cancer drugs is expected to be completed by the end of September. The relevant person in charge of the National Health Insurance Administration said that the proposed drugs proposed by experts are high clinical value, high innovation, high benefit to patients necessary for the treatment of blood tumors and solid tumors, covering non-small cell lung cancer, colorectal cancer, kidney cell carcinoma, melanoma, chronic granulocytic leukemia, lymphocytic cancer, multiple myeloma and other cancers. It is worth noting that inclusion in the list of negotiations does not mean entering the medical insurance catalogue, and in April last year, the Ministry of Human And Social Affairs published a list of 44 drugs to be negotiated, followed by the establishment of a special working group and monitoring group to undertake specific work and carry out full supervision, and organized experts to negotiate with the relevant enterprises, and finally, 36 successful drugsMost of the 18 cancer drugs announced this time are still within the time limit for the protection of exclusive patented drugs, and negotiations are difficult. In addition, the recent executive meeting of the State Council decided to put the effectiveness and safety of clear, cost-effective than significant 187 kinds of Chinese and Western medicine into the national list of essential drugs. The industry said that the update of the health insurance directory should be normal after, the previous six years have not updated the health insurance directoryAccording to the survey, the medical insurance catalog of drug waste more, so the state now to the medical insurance catalog to adjust, the waste of drugs out, the safety of clear, cost-effective than the significant 187 kinds of Chinese and Western medicine adjusted to the basic drug catalog, the total variety will be expanded to 685 kinds, the basic drug needs of the common people have a more comprehensive protection. According to media reports, this adjustment, some serious adverse reactions, after evaluation should not be used as a basic drug varieties will be the focusThe costly and no clear efficacy of the so-called "god medicine", auxiliary drugs will be abandoned.